57 related articles for article (PubMed ID: 17475843)
1. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
2. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.
Nishio S; Yamada N; Ohyama H; Yamanegi K; Nakasho K; Hata M; Nakamura Y; Fukunaga S; Futani H; Yoshiya S; Ueda H; Taniguchi M; Okamura H; Terada N
Cancer Sci; 2008 Jan; 99(1):113-20. PubMed ID: 17949451
[TBL] [Abstract][Full Text] [Related]
3. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
[TBL] [Abstract][Full Text] [Related]
4. The effects of alphaGalCer-induced TCRValpha24 Vbeta11(+) natural killer T cells on NK cell cytotoxicity in umbilical cord blood.
Ueda Y; Hagihara M; Gansuvd B; Yu Y; Masui A; Okamoto A; Higuchi A; Tazume K; Kato S; Hotta T
Cancer Immunol Immunother; 2003 Oct; 52(10):625-31. PubMed ID: 12802518
[TBL] [Abstract][Full Text] [Related]
5. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide.
Togashi Y; Chamoto K; Wakita D; Tsutsumi N; Iwakura Y; Matsubara N; Kitamura H; Nishimura T
Cancer Sci; 2007 May; 98(5):721-5. PubMed ID: 17359285
[TBL] [Abstract][Full Text] [Related]
6. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.
Chang YJ; Huang JR; Tsai YC; Hung JT; Wu D; Fujio M; Wong CH; Yu AL
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10299-304. PubMed ID: 17566107
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
8. Natural killer T cell-mediated antitumor immune responses and their clinical applications.
Seino K; Motohashi S; Fujisawa T; Nakayama T; Taniguchi M
Cancer Sci; 2006 Sep; 97(9):807-12. PubMed ID: 16805854
[TBL] [Abstract][Full Text] [Related]
9. A Designed
Ma J; He P; Zhao C; Ren Q; Dong Z; Qiu J; Jing Y; Liu S; Du Y
Adv Sci (Weinh); 2020 Jul; 7(14):2000609. PubMed ID: 32714765
[TBL] [Abstract][Full Text] [Related]
10. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency.
Stanic AK; De Silva AD; Park JJ; Sriram V; Ichikawa S; Hirabyashi Y; Hayakawa K; Van Kaer L; Brutkiewicz RR; Joyce S
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1849-54. PubMed ID: 12576547
[TBL] [Abstract][Full Text] [Related]
11. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor.
Zajonc DM; Cantu C; Mattner J; Zhou D; Savage PB; Bendelac A; Wilson IA; Teyton L
Nat Immunol; 2005 Aug; 6(8):810-8. PubMed ID: 16007091
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of lipids obtained from γ-irradiated PBMCs in dendritic cell-mediated skin inflammation.
Laggner M; Copic D; Nemec L; Vorstandlechner V; Gugerell A; Gruber F; Peterbauer A; Ankersmit HJ; Mildner M
EBioMedicine; 2020 May; 55():102774. PubMed ID: 32403085
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y
Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880
[TBL] [Abstract][Full Text] [Related]
14. Cutting edge: genetic characterization of IFN-producing killer dendritic cells.
Guimont-Desrochers F; Cappello ZJ; Chagnon M; McDuffie M; Lesage S
J Immunol; 2009 May; 182(9):5193-7. PubMed ID: 19380763
[TBL] [Abstract][Full Text] [Related]
15. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
Barclay AN; Van den Berg TK
Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
[TBL] [Abstract][Full Text] [Related]
16. Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis.
Okamoto T; Murata Y; Hasegawa D; Yoshida M; Tanaka D; Ueda T; Hazama D; Oduori OS; Komori S; Takai T; Saito Y; Kotani T; Kosaka Y; Maniwa Y; Matozaki T
Cancer Sci; 2023 May; 114(5):1871-1881. PubMed ID: 36788737
[TBL] [Abstract][Full Text] [Related]
17. CD47 Deficiency Ameliorates Ocular Autoimmune Inflammation.
Okunuki Y; Tabor SJ; Lee MY; Connor KM
Front Immunol; 2021; 12():680568. PubMed ID: 34093583
[TBL] [Abstract][Full Text] [Related]
18. α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials.
Zhang Y; Springfield R; Chen S; Li X; Feng X; Moshirian R; Yang R; Yuan W
Front Immunol; 2019; 10():1126. PubMed ID: 31244823
[TBL] [Abstract][Full Text] [Related]
19. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
Murata Y; Saito Y; Kotani T; Matozaki T
Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
[TBL] [Abstract][Full Text] [Related]
20. Anti-human SIRPα antibody is a new tool for cancer immunotherapy.
Murata Y; Tanaka D; Hazama D; Yanagita T; Saito Y; Kotani T; Oldenborg PA; Matozaki T
Cancer Sci; 2018 May; 109(5):1300-1308. PubMed ID: 29473266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
